Boundless Bio, Inc. (BOLD)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XPAR Summary
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know
Boundless Bio, Inc. (BOLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
January Effect Builds Up Momentum: 5 Small-Cap Stocks to Buy
After logging its worst month, the Russell 2000 Index is up 0.4% in the initial week of 2025, indicating that the "January Effect" is building up momentum.
Boundless Bio, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3 | $3.3 | $7.32 | $4.02 | 121.82% |
Boundless Bio, Inc. (BOLD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Boundless Bio, Inc. ever had a stock split?
Boundless Bio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Zachary Hornby CEO | NASDAQ (NGS) Exchange | 10170A100 CUSIP |
| US Country | 28 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Boundless Bio, Inc. is a trailblazing clinical-stage oncology company focused on crafting innovative cancer therapeutics. It primarily addresses the significant unmet needs of patients suffering from oncogene amplified tumors by aiming at a novel target - extrachromosomal DNA (ecDNA). This approach signifies a paradigm shift in oncology treatment, potentially offering new hope where traditional therapies fail. Originally founded as Pretzel Therapeutics, Inc. in 2018, the company underwent a rebranding to Boundless Bio, Inc. in July 2019. With its headquarters nestled in San Diego, California, Boundless Bio is at the forefront of translating groundbreaking science into life-saving treatments.
Products and Services
- BBI-355
- BBI-825
- ecDTx 3 Program
An oral inhibitor designed to target checkpoint kinase 1, BBI-355 stands at the forefront of Boundless Bio's innovative portfolio. Currently in a Phase 1/2 clinical trial, this leading product candidate is aimed at patients with cancers characterized by oncogene amplification. By focusing on checkpoint kinase 1, BBI-355 strives to disrupt the cell cycle of cancer cells, hindering their ability to reproduce and grow.
As another critical component of Boundless Bio's arsenal against cancer, BBI-825 is an oral inhibitor targeting ribonucleotide reductase. This enzyme plays a vital role in DNA replication and repair, making it a strategic target for cancer therapy. BBI-825 is under investigation in a Phase 1/2 clinical trial targeting cancer patients who have developed resistance due to gene amplifications. By inhibiting ribonucleotide reductase, BBI-825 aims to prevent cancer cells from proliferating.
Targeting a kinesin involved in the cellular mechanism responsible for the segregation of ecDNA, the ecDTx 3 program represents Boundless Bio’s innovative approach to cancer therapy. By focusing on this specific kinesin, the ecDTx 3 program aims to disrupt the distribution and function of ecDNA within cancer cells, curtailing their ability to thrive and spread. This program highlights Boundless Bio's commitment to exploiting novel targets within the cancer genome and ecDNA to develop groundbreaking treatments.
